Systemic lupus erythematosus

61 trials 29 recruiting MedDRA PT
61 Registered trials
29 Recruiting
30 Unique sponsors
31 Unique IMPs
54 Commercial trials
Drug classes (ATC)
— ATC code not specified 48
L Oncology (ATC L) 11
J Anti-infectives (ATC J) 2
H Endocrinology (ATC H) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 14 substances
Monoclonal antibody 2 substances
Monoclonal antibody (tumor, humanized) 2 substances
CAR-T cell therapy 2 substances
Monoclonal antibody (immune) 2 substances
Alkylating agent 2 substances
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (human) 1 substance
JAK inhibitor 1 substance
FcRn antagonist 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Antimetabolite 1 substance
Corticosteroid 1 substance
Phase III: 17 Phase II/III: 3 Phase II: 13 Phase I/II: 5 Phase IV: 3 Phase I: 5 Phase I (Other): 15 Phase I (First in Human): 1

Filter these 61 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 61 trials

Phase III

17 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    UPADACITINIB
    2023-503655-10-00 16 countries 2023 n=251
    Ended
  • AstraZeneca AB Commercial
    ANIFROLUMAB
    2022-502289-25-00 6 countries 2024 n=20
    Recruiting
  • AstraZeneca AB Commercial
    ANIFROLUMAB
    2025-523670-17-00 3 countries n=55
    Pending
  • Biogen Idec Research Limited Commercial
    LITIFILIMAB
    2023-505635-13-00 13 countries 2022 n=279
    Ended
  • Biogen Idec Research Limited Commercial
    LITIFILIMAB
    2023-505695-30-00 6 countries 2021 n=170
    Ended
  • Biogen Idec Research Limited Commercial
    LITIFILIMAB
    2023-505696-74-00 7 countries 2022 n=107
    Ended
  • F. Hoffmann-La Roche AG Commercial
    OBINUTUZUMAB
    2023-504774-38-00 5 countries 2021 n=68
    Ended
  • Janssen - Cilag International Commercial
    NIPOCALIMAB
    2025-523552-31-00 15 countries 2026 n=271
    Recruiting
  • Novartis Pharma AG Commercial
    IANALUMAB
    2023-505929-14-00 11 countries 2024 n=161
    Recruiting
  • Novartis Pharma AG Commercial
    IANALUMAB
    2023-508498-97-00 7 countries 2023 n=122
    Ended
  • Novartis Pharma AG Commercial
    IANALUMAB
    2023-508499-12-00 4 countries 2023 n=67
    Ended
  • UCB Biopharma Commercial
    DAPIROLIZUMAB PEGOL
    2023-506368-14-00 13 countries 2021 n=255
    Ended
  • UCB Biopharma Commercial
    DAPIROLIZUMAB PEGOL
    2023-508191-11-00 9 countries 2024 n=109
    Recruiting
  • Viatris Innovation GmbH Commercial
    CENERIMOD
    2024-514354-67-00 9 countries 2024 n=172
    Recruiting
  • Viatris Innovation GmbH Commercial
    CENERIMOD
    2024-515870-28-00 5 countries 2024 n=100
    Ended
  • Viatris Innovation GmbH Commercial
    CENERIMOD
    2024-515871-37-00 5 countries 2024 n=92
    Ended
  • Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher Academic
    IMP not specified
    2024-517753-27-01 1 country n=90
    Pending

Phase II/III

3 trials
  • AstraZeneca AB Commercial
    ANIFROLUMAB
    2024-513031-24-00 5 countries 2021 n=96
    Ended
  • Academisch Ziekenhuis Leiden Academic
    BELIMUMAB; RITUXIMAB
    2023-507867-20-00 1 country 2018 n=30
    Recruiting
  • Academisch Ziekenhuis Leiden Academic
    BELIMUMAB; RITUXIMAB
    2023-507867-20-00 1 country 2018 n=30
    Recruiting

Phase II

13 trials
  • Alumis Inc. Commercial
    ESK-001
    2022-502105-15-00 8 countries 2023 n=136
    Ended
  • Autolus Limited Commercial
    AUTO4; AUTOLOGOUS ENRICHED T CELLS RETROVIRALLY TRANSDUCED TO EXPRESS TWO CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD22; RITUXIMAB
    2024-511684-28-00 1 country 2025 n=21 Orphan
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    AFIMETORAN BESILATE DIHYDRATE
    2023-504320-25-00 6 countries 2021 n=86
    Ended
  • Celgene Corp. Commercial
    CC-97540
    2024-519278-37-00 9 countries 2025 n=35
    Halted
  • F. Hoffmann-La Roche AG Commercial
    MOSUNETUZUMAB
    2024-519930-22-00 1 country 2026 n=5
    Recruiting
  • Galapagos Commercial
    GLPG3667 FUMARATE
    2023-503183-16-00 6 countries 2024 n=70
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    BELIMUMAB
    2023-509413-37-00 2 countries 2020 n=9
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    BELIMUMAB
    2024-512730-15-00 1 country 2012 n=6
    Ended
  • Novartis Pharma AG Commercial
    IANALUMAB
    2023-508996-35-00 7 countries 2024 n=69
    Recruiting
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2023-510150-17-00 13 countries 2024 n=93
    Recruiting
  • Pfizer Inc. Commercial
    HUMANISED IGG1K MONOCLONAL ANTIBODY AGAINST INTERFERON BETA
    2023-503343-33-00 2 countries 2023 n=10
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    FREXALIMAB
    2023-508654-26-00 4 countries 2022 n=44
    Ended
  • Hospices Civils De Lyon Academic
    ABACAVIR, LAMIVUDINE
    2023-508611-22-00 1 country 2026 n=72
    Recruiting

Phase I/II

5 trials
  • Miltenyi Biomedicine GmbH Commercial
    IMP not specified
    2023-507654-33-00 1 country 2024 n=30
    Recruiting
  • Miltenyi Biomedicine GmbH Commercial
    AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CD19
    2024-516819-24-00 1 country 2023 n=33
    Recruiting
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2023-510081-27-00 3 countries 2023 n=19
    Ended
  • Universitaetsklinikum Heidelberg AöR Academic
    CNTY-101
    2024-519532-16-00 1 country 2025 n=12
    Recruiting
  • Universitaetsklinikum Heidelberg AöR Academic
    IDECABTAGENE VICLEUCEL
    2025-521530-28-00 1 country 2026 n=15 Orphan
    Recruiting

Phase IV

3 trials
  • Glaxosmithkline Research & Development Limited Commercial
    BELIMUMAB
    2023-509146-35-00 6 countries 2025 n=93
    Recruiting
  • Azienda Ospedaliero Universitaria Pisana Academic
    PREDNISONE
    2024-518580-35-00 1 country 2024 n=252
    Recruiting
  • Region Skane Academic
    RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-FUSION CONFORMATION, ADJUVANTED WITH AS01E; RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A, RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP B, STABILIZED PREFUSION F PROTEIN 847B
    2024-518191-31-00 1 country n=180
    Pending

Phase I

5 trials
  • AstraZeneca AB Commercial
    IMP not specified
    2024-519015-34-00 4 countries 2025 n=32
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IMP not specified
    2024-517681-41-00 6 countries 2025 n=93
    Recruiting
  • CRISPR Therapeutics AG Commercial
    IMP not specified
    2024-518528-54-00 2 countries 2025 n=38
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2022-502632-39-00 5 countries 2023 n=35
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    IMP not specified
    2024-514186-18-00 2 countries 2025 n=15
    Recruiting

Phase I (Other)

15 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2024-519157-10-00 2 countries 2025 n=18
    Recruiting
  • AstraZeneca AB Commercial
    IMP not specified
    2025-522273-10-00 3 countries 2026 n=15
    Recruiting
  • Autolus Limited Commercial
    IMP not specified
    2023-508236-60-00 1 country 2024 n=6
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IMP not specified
    2022-503009-39-00 6 countries 2024 n=37
    Ended
  • Celgene Corp. Commercial
    IMP not specified
    2023-503823-24-01 5 countries 2024 n=126
    Halted
  • Century Therapeutics Inc. Commercial
    IMP not specified
    2024-518797-13-00 3 countries 2025 n=16
    Ended
  • Century Therapeutics Inc. Commercial
    IMP not specified
    2024-520222-11-00 3 countries 2026 n=15
    Recruiting
  • Climb Bio Inc. Commercial
    IMP not specified
    2024-520385-57-00 1 country n=3
    Not authorised
  • Climb Bio Inc. Commercial
    IMP not specified
    2024-520385-57-01 4 countries 2025 n=11
    Recruiting
  • Cullinan Therapeutics Inc. Commercial
    IMP not specified
    2024-518780-36-00 6 countries 2025 n=44
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2023-509188-26-00 1 country 2022 n=7
    Ended
  • Galapagos Commercial
    IMP not specified
    2023-504422-19-00 2 countries n=20
    Ended
  • Genentech Inc. Commercial
    IMP not specified
    2025-522904-26-00 4 countries n=17
    Pending
  • IGM Biosciences Inc. Commercial
    IMP not specified
    2023-506499-29-00 1 country 2024 n=6
    Ended
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-510025-14-00 5 countries 2024 n=32
    Ended

Phase I (First in Human)

1 trial
  • Cabaletta Bio Inc. Commercial
    CABA-201; CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE MONOHYDRATE; FLUDARABINE PHOSPHATE
    2023-507613-10-01 2 countries 2025 n=6
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 7 Phase I (Other), Phase II, Phase III, Phase I/II 3
AstraZeneca AB Commercial 5 Phase I, Phase II/III, Phase I (Other), Phase III 3
F. Hoffmann-La Roche AG Commercial 4 Phase I, Phase I (Other), Phase II, Phase III 1
Glaxosmithkline Research & Development Limited Commercial 4 Phase I, Phase II, Phase IV 2
Bristol-Myers Squibb Services Unlimited Company Commercial 3 Phase I, Phase I (Other), Phase II 1
Biogen Idec Research Limited Commercial 3 Phase III 0
Viatris Innovation GmbH Commercial 3 Phase III 1
AbbVie Deutschland GmbH & Co. KG Commercial 2 Phase I (Other), Phase III 1
Autolus Limited Commercial 2 Phase I (Other), Phase II 2
Celgene Corp. Commercial 2 Phase I (Other), Phase II 0
Century Therapeutics Inc. Commercial 2 Phase I (Other) 1
Climb Bio Inc. Commercial 2 Phase I (Other) 1
Galapagos Commercial 2 Phase I (Other), Phase II 0
UCB Biopharma Commercial 2 Phase III 1
Miltenyi Biomedicine GmbH Commercial 2 Phase I/II 2
Academisch Ziekenhuis Leiden Academic 2 Phase II/III 2
Universitaetsklinikum Heidelberg AöR Academic 2 Phase I/II 2
CRISPR Therapeutics AG Commercial 1 Phase I 1
Cullinan Therapeutics Inc. Commercial 1 Phase I (Other) 1
Genentech Inc. Commercial 1 Phase I (Other) 0
New trials by year
2020
1
2021
5
2022
4
2023
8
2024
16
2025
13
2026
6
← All indication landscapes